Ethics and
Compliance

 

Ethics and Compliance

 

At Exelixis, we strive for the highest standards of business conduct and ethics. The Exelixis Corporate Code of Conduct (the “Code”) reflects the business practices and principles of behavior that support this commitment. We are dedicated to creating a culture that encourages responsible corporate action at every level in our organization. It is expected that all of Exelixis’ officers, employees, directors, agents and contractors will maintain the standards established in our Code of Conduct and adhere to the policies created in support of the Code.

Exelixis provides multiple channels for asking questions and raising compliance concerns. We have open door, anti-retaliation, and confidentiality policies to encourage and protect individuals who raise a good faith concern. Exelixis adheres to an “Open Door Policy” and encourages staff to discuss all issues, concerns, problems, and suggestions with their immediate supervisors or other managers, including members of the Ethics Committee, without fear of retaliation and with the assurance that the matter will be kept as confidential as possible. Exelixis’ Ethics Helpline also allows individuals to request guidance or report a concern anonymously. The Ethics Helpline can be reached by phone or online via the web-reporting tool. This resource is accessible 24 hours a day, 7 days a week, 365 days a year and is operated by specially trained third-party representatives:

California Compliance Declaration

Exelixis, Inc. is committed to establishing and maintaining a comprehensive and effective compliance program in accordance with California SB 1765 (California Business & Professions Code 119400, 119402), and the Office of Inspector General, U.S. Department of Health and Human Services, “Compliance Program Guidance for Pharmaceutical Manufacturers” (OIG Guidance).

Our Compliance Program reflects our unwavering commitment to the highest standards of corporate conduct and integrity.

Click here to view our Comprehensive Compliance Program.

Vermont Pharmaceutical Marketer Price Disclosure

Vermont law 18 V.S.A. § 4633 requires pharmaceutical marketers to disclose to Vermont doctors and other prescribers the prices of the drugs they market as well as the prices of other drugs in the same therapeutic class.

This page allows those doctors and other prescribers’ access to this information for applicable products that are manufactured and marketed by Exelixis.

Please choose either “Long form” or “Short form” below.

Vermont COMETRIQ® Short Form
Vermont COMETRIQ Long Form
Vermont CABOMETYX® Short Form
Vermont CABOMETYX Long Form